2026

Cambridge, Mass. and Singapore – Cirrus Therapeutics today announced several business and pipeline updates to support its growth as a leading global ocular immunology company advancing first-in-class and best-in-class therapies to extend the ocular healthspan of patients with chronic blinding diseases. “Our presence in Singapore well positions us to leverage critical research, clinical development and partnering […]

During his time as a Blavatnik Fellow, Ying Kai Chan co-founded Cirrus Therapeutics, a company developing first-in-class and best-in-classs ocular medicines, which just recently celebrated an $11 million seed raise. We spoke with Kai about his path to HBS, the Fellowship’s role in shaping his entrepreneurial journey, and what’s ahead for Cirrus.